(July 3, 2018, 2:53 PM EDT) -- ALEXANDRIA, Va. — The inventors of a method of targeting certain pharmacokinetic (PK) and pharmacodynamic (PD) parameters with a drug formulation extended their patent protection by eight years when they claimed an inherent property of the drug that was discovered during a routine clinical trial, Dr. Reddy’s Laboratories Inc. asserts in a July 2 petition for inter partes review (IPR) by the Patent Trial and Appeal Board (Dr. Reddy’s Laboratories Inc. v. Pozen Inc., et al., No. IPR2018-001341, PTAB)....